{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:38:09Z","timestamp":1762508289588,"version":"3.41.0"},"reference-count":49,"publisher":"Scientific Scholar","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T00:00:00Z","timestamp":1600905600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Deanship of Scientific Research, Imam Abdulrahman Bin Faisal University"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Arabian Journal of Chemistry"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.arabjc.2020.09.037","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T06:47:44Z","timestamp":1601534864000},"page":"8069-8079","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["TAT-peptide conjugated repurposing drug against SARS-CoV-2 main protease (3CLpro): Potential therapeutic intervention to combat COVID-19"],"prefix":"10.25259","volume":"13","author":[{"given":"Mohammad Azam","family":"Ansari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qazi Mohammad Sajid","family":"Jamal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suriya","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1491-6402","authenticated-orcid":false,"given":"Ahmad","family":"Almatroudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad A.","family":"Alzohairy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7909-4377","authenticated-orcid":false,"given":"Mohammad N.","family":"Alomary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6399-9825","authenticated-orcid":false,"given":"Takshashila","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1815-7287","authenticated-orcid":false,"given":"Ali H.","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Farooq","family":"Adil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mujeeb","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Shaheer Malik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","reference":[{"key":"10.1016\/j.arabjc.2020.09.037_b0005","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1126\/science.1085658","article-title":"Coronavirus main proteinase (3CLpro) structure: Basis for design of anti-SARS drugs","volume":"300","author":"Anand","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.arabjc.2020.09.037_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17425247.2020.1813712","article-title":"Lipid-based nano delivery of Tat-peptide conjugated drug or vaccine\u2013promising therapeutic strategy for SARS-CoV-2 treatment","volume":"31","author":"Ansari","year":"2020","journal-title":"Exp. Opin. Drug Deliv."},{"key":"10.1016\/j.arabjc.2020.09.037_b0015","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.febslet.2013.04.031","article-title":"Cell-penetrating peptides: 20 years later, where do we stand?","volume":"587","author":"Bechara","year":"2013","journal-title":"FEBS Lett."},{"key":"10.1016\/j.arabjc.2020.09.037_b0020","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/bioinformatics\/btq662","article-title":"Toward the estimation of the absolute quality of individual protein structure models","volume":"27","author":"Benkert","year":"2011","journal-title":"Bioinformatics"},{"key":"10.1016\/j.arabjc.2020.09.037_b0025","article-title":"A SARS-CoV-2 vaccine candidate: In-silico cloning and validation","volume":"20","author":"Bhattacharya","year":"2020","journal-title":"Inf. Med. Unlocked"},{"key":"10.1016\/j.arabjc.2020.09.037_b0030","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/jmv.25736","article-title":"Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): Immunoinformatics approach","volume":"92","author":"Bhattacharya","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.arabjc.2020.09.037_b0035","first-page":"4016","article-title":"SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options","volume":"24","author":"Chakraborty","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"10.1016\/j.arabjc.2020.09.037_b0040","doi-asserted-by":"crossref","first-page":"242","DOI":"10.4103\/1995-7645.281613","article-title":"The 2019 novel coronavirus disease (COVID-19) pandemic: A zoonotic prospective","volume":"13","author":"Chakraborty","year":"2020","journal-title":"Asian Pacif. J. Trop. Med."},{"key":"10.1016\/j.arabjc.2020.09.037_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.arcmed.2020.05.021","article-title":"Extensive Partnership, Collaboration, and Teamwork is Required to Stop the COVID-19 Outbreak","author":"Chakraborty","year":"2020","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.arabjc.2020.09.037_b0050","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/22221751.2020.1719902","article-title":"Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan","volume":"9","author":"Chan","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.arabjc.2020.09.037_b0055","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/jmv.26234","article-title":"Emerging coronaviruses: genome structure, replication, and pathogenesis","volume":"92","author":"Chen","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.arabjc.2020.09.037_b0060","first-page":"16","article-title":"All-atom structure validation for macromolecular crystallography","volume":"D66","author":"Chenn","year":"2010","journal-title":"Acta Cryst."},{"key":"10.1016\/j.arabjc.2020.09.037_b0065","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.bpj.2010.03.065","article-title":"Cell-penetrating HIV1 TAT peptides can generate pores in model membranes","volume":"7","author":"Ciobanasu","year":"2010","journal-title":"Biophys. J."},{"key":"10.1016\/j.arabjc.2020.09.037_b0070","article-title":"A novel cell-penetrating peptide derived from human eosinophil cationic protein","volume":"8","author":"Fang","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.arabjc.2020.09.037_b0075","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci. Trends."},{"key":"10.1016\/j.arabjc.2020.09.037_b0080","article-title":"Nanotechnology for COVID-19: Therapeutics and Vaccine Research","author":"Gaurav","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.arabjc.2020.09.037_b0085","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Age."},{"key":"10.1016\/j.arabjc.2020.09.037_b0090","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3390\/v12020135","article-title":"Return of the Coronavirus: 2019-nCoV","volume":"12","author":"Gralinski","year":"2020","journal-title":"Viruses."},{"key":"10.1016\/j.arabjc.2020.09.037_b0095","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","volume":"368","author":"Hang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.arabjc.2020.09.037_b0100","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1111\/febs.12936","article-title":"From SARS to MERS: Crystallographic studies on coronaviral proteases enable antiviral drug design","volume":"281","author":"Hilgenfeld","year":"2014","journal-title":"FEBS J."},{"key":"10.1016\/j.arabjc.2020.09.037_b0105","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJMoa2001191","article-title":"First case of 2019 novel coronavirus in the United States","volume":"382","author":"Holshue","year":"2020","journal-title":"N. Engl. J. Med."},{"unstructured":"https:\/\/milken-institute-covid-19-tracker.webflow.io\/ LAST UPDATED:SEPTEMBER 10, 2020 8:26 AMPACIFIC.","key":"10.1016\/j.arabjc.2020.09.037_b0110"},{"key":"10.1016\/j.arabjc.2020.09.037_b0125","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.arabjc.2020.09.037_b0130","doi-asserted-by":"crossref","first-page":"W449","DOI":"10.1093\/nar\/gkw329","article-title":"PEP-FOLD3: faster de novo structure prediction for linear peptides in solution and in complex","volume":"44","author":"Lamiable","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.arabjc.2020.09.037_b0135","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/17425247.2017.1360863","article-title":"Nanomedicine formulations for the delivery of antiviral drugs: a promising solution for the treatment of viral infections","volume":"15","author":"Lembo","year":"2018","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.arabjc.2020.09.037_b0140","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","article-title":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV)","volume":"19","author":"Li","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.arabjc.2020.09.037_b0145","article-title":"Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV","author":"Liu","year":"2020","journal-title":"ChemBioChem"},{"key":"10.1016\/j.arabjc.2020.09.037_b0150","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jgg.2020.02.001","article-title":"Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines","volume":"47","author":"Liu","year":"2020","journal-title":"J. Gen. Genom."},{"issue":"19","key":"10.1016\/j.arabjc.2020.09.037_b0160","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B","article-title":"Automate Docking Using a Lamarckian Genetic Algorithm and and Empirical Binding Free Energy Function","volume":"1998","author":"Morris","year":"1998","journal-title":"J. Comput. Chem."},{"unstructured":"https:\/\/covid19.who.int\/ Updated: September 11, 2020.","key":"10.1016\/j.arabjc.2020.09.037_b0120"},{"doi-asserted-by":"crossref","unstructured":"Nguyen, D., Gao, K., Chen, J., Wang, R., Wei, G., 2020. Potentially highly potent drugs for 2019-nCoV. bioRxiv. https:\/\/doi.org\/10.1101\/2020.02.05.936013.","key":"10.1016\/j.arabjc.2020.09.037_b0165","DOI":"10.1101\/2020.02.05.936013"},{"key":"10.1016\/j.arabjc.2020.09.037_b0170","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1021\/bc0255900","article-title":"Tat-conjugated synthetic macromolecules facilitate cytoplasmic drug delivery to human ovarian carcinoma cells","volume":"14","author":"Nori","year":"2003","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.arabjc.2020.09.037_b0175","series-title":"Cell-Penetrating Peptides","first-page":"223","article-title":"The antimicrobial and antiviral applications of cell-penetrating peptides","author":"P\u00e4rn","year":"2015"},{"key":"10.1016\/j.arabjc.2020.09.037_b0180","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1001\/jama.2020.0757","article-title":"Coronavirus infections\u2014more than just the common cold","volume":"323","author":"Paules","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.arabjc.2020.09.037_b0185","doi-asserted-by":"crossref","first-page":"10300","DOI":"10.1039\/C9CP01543D","article-title":"Molecular mechanism of HIV-1 TAT peptide and its conjugated gold nanoparticles translocating across lipid membranes","volume":"21","author":"Quan","year":"2019","journal-title":"PCCP"},{"key":"10.1016\/j.arabjc.2020.09.037_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.sjbs.2020.05.024","article-title":"Current scenario of COVID-19 in pediatric age group and physiology of immune and thymus response","author":"Rehman","year":"2020","journal-title":"Saudi J. Biol. Sci."},{"key":"10.1016\/j.arabjc.2020.09.037_b0195","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.arcmed.2020.05.009","article-title":"Tocilizumab: A therapeutic option for the treatment of cytokine storm syndrome in COVID-19","volume":"51","author":"Saha","year":"2020","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.arabjc.2020.09.037_b0200","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.arcmed.2020.05.001","article-title":"Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know More","volume":"51","author":"Saha","year":"2020","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.arabjc.2020.09.037_b0205","doi-asserted-by":"crossref","first-page":"W363","DOI":"10.1093\/nar\/gki481","article-title":"PatchDock and SymmDock: servers for rigid and symmetric docking","volume":"33","author":"Schneidman-Duhovny","year":"2005","journal-title":"Nucl. Acids. Res."},{"doi-asserted-by":"crossref","unstructured":"Sekhar, T., 2020. Virtual Screening based prediction of potential drugs for COVID-19. https:\/\/doi.org\/10.20944\/preprints202002.0418.v2. Preprints (www.preprints.org).","key":"10.1016\/j.arabjc.2020.09.037_b0210","DOI":"10.20944\/preprints202002.0418.v2"},{"key":"10.1016\/j.arabjc.2020.09.037_b0215","doi-asserted-by":"crossref","first-page":"465","DOI":"10.4155\/tde-2019-0042","article-title":"Cell-penetrating peptides in vaccine delivery: facts, challenges and perspectives","volume":"10","author":"Skwarczynski","year":"2019","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.arabjc.2020.09.037_b0220","doi-asserted-by":"crossref","first-page":"37252","DOI":"10.18632\/oncotarget.26442","article-title":"Cell penetrating peptides in preclinical and clinical cancer diagnosis and therapy","volume":"9","author":"Tripathi","year":"2018","journal-title":"Oncotarget."},{"key":"10.1016\/j.arabjc.2020.09.037_b0225","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/jcc.21367","article-title":"CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields","volume":"31","author":"Vanommeslaeghe","year":"2010","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.arabjc.2020.09.037_b0230","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.arabjc.2020.09.037_b0235","doi-asserted-by":"crossref","first-page":"64","DOI":"10.5582\/bst.2020.01030","article-title":"Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment","volume":"14","author":"Wang","year":"2020","journal-title":"Bioscience Trends."},{"issue":"6","key":"10.1016\/j.arabjc.2020.09.037_b0240","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1021\/acsnano.0c03697","article-title":"Toward Nanotechnology-Enabled Approaches against the COVID-19 Pandemic","volume":"14","author":"Weiss","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.arabjc.2020.09.037_b0245","doi-asserted-by":"crossref","first-page":"W296","DOI":"10.1093\/nar\/gky427","article-title":"SWISS-MODEL: homology modelling of protein structures and complexes","volume":"46","author":"Waterhouse","year":"2018","journal-title":"Nucleic Acids Res."},{"doi-asserted-by":"crossref","unstructured":"Xu, Z., Peng, C., Shi, Y., Zhu, Z., Mu, K., Wang, X., Zhu, W., 2020. Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation. bioRxiv. https:\/\/doi.org\/10.1101\/2020.01.27.921627.","key":"10.1016\/j.arabjc.2020.09.037_b0250","DOI":"10.1101\/2020.01.27.921627"},{"key":"10.1016\/j.arabjc.2020.09.037_b0255","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/resp.13196","article-title":"MERS, SARS and other coronaviruses as causes of pneumonia","volume":"23","author":"Yin","year":"2018","journal-title":"Respirology"}],"container-title":["Arabian Journal of Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878535220303713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878535220303713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T21:04:05Z","timestamp":1751058245000},"score":1,"resource":{"primary":{"URL":"https:\/\/arabjchem.org\/tat-peptide-conjugated-repurposing-drug-against-sars-cov-2-main-protease-3clpro-potential-therapeutic-intervention-to-combat-covid-19\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1878535220303713"],"URL":"https:\/\/doi.org\/10.1016\/j.arabjc.2020.09.037","relation":{},"ISSN":["1878-5352"],"issn-type":[{"type":"print","value":"1878-5352"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TAT-peptide conjugated repurposing drug against SARS-CoV-2 main protease (3CLpro): Potential therapeutic intervention to combat COVID-19","name":"articletitle","label":"Article Title"},{"value":"Arabian Journal of Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arabjc.2020.09.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V. on behalf of King Saud University.","name":"copyright","label":"Copyright"}]}}